Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165841 · ClinicalTrials.gov registry record · Phase 2
Maintenance Intermittent Therapy for Symptomatic GERD Patients
A Phase 2 study of Gastroesophageal Reflux Disease, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00165841 is a Phase 2 study of Gastroesophageal Reflux Disease that has completed, run by Eisai. The registered enrollment target is 200 participants, below the 339-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00165841, a Phase 2 study of Gastroesophageal Reflux Disease, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study to determine the efficacy of 20 mg of rabeprazole given as a maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal Reflux Disease (s-GERD).
Conditions Studied
Interventions
- DRUG Rabeprazole 20 mg
Study Locations (1)
California
- Quality Care Medical Center Inc. - Vista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2004-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00165841
The ClinicalTrials.gov registry entry for NCT00165841 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 339-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (41% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastroesophageal Reflux Disease appearing as the primary indexed condition, and to 1 intervention - of which Rabeprazole 20 mg is the first listed.
NCT00165841 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00165841 about?
NCT00165841 is a clinical study titled "Maintenance Intermittent Therapy for Symptomatic GERD Patients". The purpose of this study to determine the efficacy of 20 mg of rabeprazole given as a maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal Reflux Disease (s-GERD).
What is the current status of trial NCT00165841?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2004-10. Estimated completion is 2008-06.
What conditions does trial NCT00165841 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux Disease.
What interventions are being tested in trial NCT00165841?
The interventions under investigation include: Rabeprazole 20 mg (DRUG).
Who is sponsoring clinical trial NCT00165841?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00165841 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents
COMPLETED · Phase 2
-
A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)
COMPLETED · Phase 2
-
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
COMPLETED · Phase 2
-
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
COMPLETED · Phase 2
-
The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.